| Year |
Citation |
Score |
| 2020 |
Bazarbashi N, Miller M. Icosapent Ethyl: Niche Drug or for the Masses? Current Cardiology Reports. 22: 104. PMID 32770402 DOI: 10.1007/S11886-020-01356-4 |
0.335 |
|
| 2020 |
Bazarbashi N, Miller M. Icosapent Ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol. Expert Review of Cardiovascular Therapy. PMID 32228246 DOI: 10.1080/14779072.2020.1749596 |
0.349 |
|
| 2020 |
Zhang Z, Bhatt DL, Zhang C, Dolman S, Boden WE, Steg P, Miller M, Brinton EA, King JB, Bress AP, Jacobson TA, Tardif J, Ballantyne CM, Kolm P, Weintraub WS. Abstract 26: Scenario Analyses of Lifetime Cost-effectiveness of Icosapent Ethyl in REDUCE-IT Circulation-Cardiovascular Quality and Outcomes. 13. DOI: 10.1161/Hcq.13.Suppl_1.26 |
0.31 |
|
| 2019 |
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Jiao L, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM. Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. Journal of the American College of Cardiology. 74: 1159-1161. PMID 31439224 DOI: 10.1016/J.Jacc.2019.06.043 |
0.31 |
|
| 2019 |
Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FK. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation. CIR0000000000000709. PMID 31422671 DOI: 10.1161/Cir.0000000000000709 |
0.331 |
|
| 2019 |
Miller M, Ballantyne CM, Bays HE, Granowitz C, Doyle RT, Juliano RA, Philip S. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). The American Journal of Cardiology. PMID 31277790 DOI: 10.1016/J.Amjcard.2019.05.057 |
0.335 |
|
| 2019 |
Park JE, Miller M. Triglycerides: Mendelian Randomization Studies Suggest Causal Role, but How to Treat in 2019? Current Cardiovascular Risk Reports. 13: 1-5. DOI: 10.1007/S12170-019-0603-3 |
0.334 |
|
| 2018 |
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. ATV0000000000000073. PMID 30580575 DOI: 10.1161/Atv.0000000000000073 |
0.318 |
|
| 2018 |
Mitchell BD, Kalra G, Ryan KA, Zhang M, Sztalryd C, Steinle NI, Taylor SI, Snitker S, Lewis JP, Miller M, Shuldiner AR, Xu H. Increased usual physical activity is associated with a blunting of the triglyceride response to a high-fat meal. Journal of Clinical Lipidology. PMID 30553757 DOI: 10.1016/J.Jacl.2018.11.006 |
0.304 |
|
| 2018 |
Miller M. Low-Density Lipoprotein Triglycerides: Widening the Atherogenic Landscape in CVD Risk Assessment. Journal of the American College of Cardiology. 72: 170-172. PMID 29976290 DOI: 10.1016/J.Jacc.2018.03.541 |
0.309 |
|
| 2018 |
Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. Journal of the American College of Cardiology. PMID 29935936 DOI: 10.1016/J.Jacc.2018.04.061 |
0.364 |
|
| 2018 |
Montasser ME, O'Hare EA, Wang X, Howard AD, McFarland R, Perry JA, Ryan KA, Rice K, Jaquish CE, Shuldiner AR, Miller M, Mitchell BD, Zaghloul NA, Chang YC. AnPseudogene on Chromosome 5q is Associated with LDL-C Levels. Circulation. PMID 29593015 DOI: 10.1161/Circulationaha.118.034016 |
0.316 |
|
| 2018 |
Miller M, Ballantyne C, Bays H, Granowitz C, Doyle R, Juliano R, Philip S. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) Reduces Potentially Atherogenic Lipid, Lipoprotein, Apolipoprotein, And Inflammatory Parameters In High-Risk, Statin-Treated Patients With Persistent Elevated Triglycerides And High-Sensitivity C-Reactive Protein: A Post Hoc Subanalysis Of The Anchor Study Journal of the American College of Cardiology. 71. DOI: 10.1016/S0735-1097(18)31933-8 |
0.333 |
|
| 2017 |
Oates CP, Koenig D, Rhyne J, Bogush N, O'Connell J, Mitchell BD, Miller M. Novel polymorphisms associated with hyperalphalipoproteinemia and apparent cardioprotection. Journal of Clinical Lipidology. PMID 29198934 DOI: 10.1016/J.Jacl.2017.10.021 |
0.327 |
|
| 2017 |
Miller M. Apolipoprotein C-III: The Small Protein With Sizeable Vascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology. 37: 1013-1014. PMID 28539488 DOI: 10.1161/Atvbaha.117.309493 |
0.321 |
|
| 2017 |
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJ, Koenig W, Lorenzatti A, Manga P, ... ... Miller M, et al. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. The New England Journal of Medicine. PMID 28304242 DOI: 10.1056/Nejmoa1701488 |
0.341 |
|
| 2017 |
Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif JC, Ketchum SB, Doyle RT, Murphy SA, Soni PN, Braeckman RA, Juliano RA, Ballantyne CM. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clinical Cardiology. PMID 28294373 DOI: 10.1002/Clc.22692 |
0.352 |
|
| 2016 |
Rosenson RS, Jacobson TA, Preiss D, Djedjos CS, Dent R, Bridges I, Miller M. Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy. PMID 27240673 DOI: 10.1007/S10557-016-6666-1 |
0.319 |
|
| 2016 |
Ahmed HM, Miller M, Nasir K, McEvoy JW, Herrington D, Blumenthal RS, Blaha MJ. Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis. American Journal of Epidemiology. 183: 875-83. PMID 27189327 DOI: 10.1093/Aje/Kwv305 |
0.349 |
|
| 2016 |
Bartlett J, Predazzi IM, Williams SM, Bush WS, Kim Y, Havas S, Toth PP, Fazio S, Miller M. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study. Circulation. Cardiovascular Quality and Outcomes. PMID 27166203 DOI: 10.1161/Circoutcomes.115.002436 |
0.346 |
|
| 2016 |
Colantonio L, Fazio S, Rosenson R, Miller M, Banach M, Safford M, Muntner P, Toth P. LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND INCIDENT CORONARY HEART DISEASE AMONG BLACKS IN THE REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE (REGARDS) STUDY Journal of the American College of Cardiology. 67: 1837. DOI: 10.1016/S0735-1097(16)31838-1 |
0.332 |
|
| 2015 |
Miller JM, Kaastra JS, Miller MC, Reynolds MT, Brown G, Cenko SB, Drake JJ, Gezari S, Guillochon J, Gultekin K, Irwin J, Levan A, Maitra D, Maksym WP, Mushotzky R, et al. Flows of X-ray gas reveal the disruption of a star by a massive black hole. Nature. 526: 542-5. PMID 26490619 DOI: 10.1038/Nature15708 |
0.581 |
|
| 2015 |
Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. Journal of the American College of Cardiology. 65: 2267-75. PMID 26022813 DOI: 10.1016/J.Jacc.2015.03.544 |
0.344 |
|
| 2015 |
Miller M. Is triglyceride therapy worth the effort? Cleveland Clinic Journal of Medicine. 82: 162-6. PMID 25932741 DOI: 10.3949/Ccjm.82A.13157 |
0.325 |
|
| 2015 |
Bagchi S, Patel P, Faram R, Burrowes S, Hossain MB, Kottilil S, Miller M, Fantry LE, Redfield RR. Underutilization of Statins for Prevention of Cardiovascular Disease among Primarily African-American HIV-Infected Patients Journal of Aids and Clinical Research. 6: 1-6. DOI: 10.4172/2155-6113.1000499 |
0.306 |
|
| 2014 |
Miller M, Kim Y, Havas S, Kwiterovich P, Fazio S. DOES LOW HDL-C INCREASE CHD RISK WHEN TG & LDL-C ARE NORMAL? THE FRAMINGHAM OFFSPRING STUDY Journal of the American College of Cardiology. 63: A1286. DOI: 10.1016/S0735-1097(14)61286-9 |
0.321 |
|
| 2013 |
Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'Agostino RB, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ. High-density lipoproteins: a consensus statement from the National Lipid Association. Journal of Clinical Lipidology. 7: 484-525. PMID 24079290 DOI: 10.1016/J.Jacl.2013.08.001 |
0.361 |
|
| 2012 |
Ballantyne CM, Miller M, Niesor EJ, Burgess T, Kallend D, Stein EA. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. American Heart Journal. 163: 515-21, 521.e1-3. PMID 22424025 DOI: 10.1016/J.Ahj.2011.11.017 |
0.34 |
|
| 2012 |
Martin SS, Blumenthal RS, Miller M. LDL cholesterol: the lower the better. Medical Clinics of North America. 96: 13-26. PMID 22391248 DOI: 10.1016/J.Mcna.2012.01.009 |
0.345 |
|
| 2011 |
Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 123: 2292-333. PMID 21502576 DOI: 10.1161/Cir.0B013E3182160726 |
0.347 |
|
| 2010 |
Shen H, Damcott CM, Rampersaud E, Pollin TI, Horenstein RB, McArdle PF, Peyser PA, Bielak LF, Post WS, Chang YP, Ryan KA, Miller M, Rumberger JA, Sheedy PF, Shelton J, et al. Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish. Archives of Internal Medicine. 170: 1850-5. PMID 21059979 DOI: 10.1001/Archinternmed.2010.384 |
0.339 |
|
| 2010 |
Miller M. Hold the patty, not the lettuce: processing foods for over a quarter century in the Nurses' Health Study. Circulation. 122: 859-860. PMID 20713894 DOI: 10.1161/Circulationaha.110.971812 |
0.305 |
|
| 2010 |
Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. Journal of the American College of Cardiology. 55: 2721-6. PMID 20399059 DOI: 10.1016/J.Jacc.2010.03.017 |
0.333 |
|
| 2010 |
Miller M. Managing mixed dyslipidemia in special populations. Preventive Cardiology. 13: 78-83. PMID 20377810 DOI: 10.1111/J.1751-7141.2009.00057.X |
0.301 |
|
| 2009 |
Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. The New England Journal of Medicine. 361: 2113-22. PMID 19915217 DOI: 10.1056/Nejmoa0907569 |
0.349 |
|
| 2009 |
Miller M. Dyslipidemia and cardiovascular risk: the importance of early prevention Qjm: An International Journal of Medicine. 102: 657-667. PMID 19498039 DOI: 10.1093/Qjmed/Hcp065 |
0.359 |
|
| 2009 |
Miller M. An Emerging Paradigm in Atherosclerosis: Focus on Subclinical Disease Postgraduate Medicine. 121: 49-59. PMID 19332962 DOI: 10.3810/Pgm.2009.03.1976 |
0.314 |
|
| 2009 |
Miller M, Beach V, Sorkin JD, Mangano C, Dobmeier C, Novacic D, Rhyne J, Vogel RA. Comparative effects of three popular diets on lipids, endothelial function, and C-reactive protein during weight maintenance. Journal of the American Dietetic Association. 109: 713-7. PMID 19328268 DOI: 10.1016/J.Jada.2008.12.023 |
0.304 |
|
| 2008 |
Dobs A, Miller M, Delucca PT, Ramsey KE, Tershakovec AM, Horn W. Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia. Journal of Clinical Lipidology. 2: 12-8. PMID 21291710 DOI: 10.1016/J.Jacl.2007.12.001 |
0.326 |
|
| 2008 |
Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (New York, N.Y.). 322: 1702-5. PMID 19074352 DOI: 10.1126/Science.1161524 |
0.309 |
|
| 2008 |
Gandotra P, Miller M. The role of triglycerides in cardiovascular risk Current Cardiology Reports. 10: 505-511. PMID 18950562 DOI: 10.1007/S11886-008-0079-0 |
0.358 |
|
| 2008 |
Miller M, Ginsberg HN, Schaefer EJ. Relative Atherogenicity and Predictive Value of Non–High-Density Lipoprotein Cholesterol for Coronary Heart Disease American Journal of Cardiology. 101: 1003-1008. PMID 18359322 DOI: 10.1016/J.Amjcard.2007.11.046 |
0.356 |
|
| 2008 |
Majeed F, Miller M. Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment. Current Opinion in Endocrinology, Diabetes and Obesity. 15: 175-181. PMID 18316954 DOI: 10.1097/Med.0B013E3282F79B0B |
0.331 |
|
| 2008 |
Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. Journal of the American College of Cardiology. 51: 724-30. PMID 18279736 DOI: 10.1016/J.Jacc.2007.10.038 |
0.307 |
|
| 2007 |
Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and cardiovascular risk reduction Clinical Therapeutics. 29: 763-777. PMID 17697898 DOI: 10.1016/J.Clinthera.2007.05.002 |
0.354 |
|
| 2007 |
Mantaring M, Rhyne J, Hong SH, Miller M. Genotypic variation in ATP-binding cassette transporter-1 (ABCA1) as contributors to the high and low high-density lipoprotein-cholesterol (HDL-C) phenotype. Translational Research. 149: 205-210. PMID 17383594 DOI: 10.1016/J.Trsl.2006.11.007 |
0.312 |
|
| 2007 |
Miller M. Optimal treatment of dyslipidemia in high-risk patients: intensive statin treatment or combination therapy? Preventive Cardiology. 10: 31-35. PMID 17215631 DOI: 10.1111/J.1520-037X.2007.05662.X |
0.334 |
|
| 2007 |
Miller M, Rhyne J, Hong SH, Friel G, Dolinar C, Riley W. Do mutations causing low HDL-C promote increased carotid intima-media thickness? Clinica Chimica Acta. 377: 273-275. PMID 17113061 DOI: 10.1016/J.Cca.2006.10.001 |
0.333 |
|
| 2007 |
Miller M, Langenberg P, Havas S. Impact of lowering triglycerides on raising HDL-C in hypertriglyceridemic and non-hypertriglyceridemic subjects. International Journal of Cardiology. 119: 192-5. PMID 17052787 DOI: 10.1016/J.Ijcard.2006.07.132 |
0.311 |
|
| 2006 |
Rhyne J, Ryan MJ, White C, Chimonas T, Miller M. The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease. Journal of Molecular Medicine. 84: 647-650. PMID 16855848 DOI: 10.1007/S00109-006-0070-4 |
0.32 |
|
| 2006 |
Miller M, Dobs A, Yuan Z, Battisti WP, Palmisano J. The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study. Current Medical Research and Opinion. 22: 343-350. PMID 16466606 DOI: 10.1185/030079906X80521 |
0.319 |
|
| 2005 |
Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Archives of Internal Medicine. 165: 2063-8. PMID 16216995 DOI: 10.1001/Archinte.165.18.2063 |
0.322 |
|
| 2005 |
Ahmad I, Zhan M, Miller M. High prevalence of C-reactive protein elevation with normal triglycerides (100-149 mg/dL): are triglyceride levels below 100 mg/dL more optimal in coronary heart disease risk assessment? The American Journal of the Medical Sciences. 329: 173-7. PMID 15832099 DOI: 10.1097/00000441-200504000-00002 |
0.322 |
|
| 2004 |
Miller M, Dobs AS, Yuan Z, Battisti WP, Borisute H, Palmisano J. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. Current Medical Research and Opinion. 20: 1087-1094. PMID 15265253 DOI: 10.1185/030079904125004105 |
0.317 |
|
| 2004 |
Miller M, Zhan M. Genetic determinants of low high-density lipoprotein cholesterol. Current Opinion in Cardiology. 19: 380-4. PMID 15218400 DOI: 10.1097/01.Hco.0000126584.12520.B5 |
0.334 |
|
| 2003 |
Miller M. Niacin as a Component of Combination Therapy for Dyslipidemia Mayo Clinic Proceedings. 78: 735-742. PMID 12934785 DOI: 10.4065/78.6.735 |
0.348 |
|
| 2003 |
Miller M, Rhyne J, Hamlette S, Birnbaum J, Rodriguez A. Genetics of HDL regulation in humans Current Opinion in Lipidology. 14: 273-279. PMID 12840658 DOI: 10.1097/00041433-200306000-00007 |
0.316 |
|
| 2003 |
Miller M. Raising an isolated low HDL-C level: why, how, and when? Cleveland Clinic Journal of Medicine. 70: 553-560. PMID 12828226 DOI: 10.3949/Ccjm.70.6.553 |
0.347 |
|
| 2003 |
Miller M, Zhan M, Georgopoulos A. Effect of desirable fasting triglycerides on the postprandial response to dietary fat. Journal of Investigative Medicine : the Official Publication of the American Federation For Clinical Research. 51: 50-5. PMID 12580321 DOI: 10.2310/6650.2003.33544 |
0.312 |
|
| 2002 |
Miller M, Cosgrove B, Havas S. Update on the role of triglycerides as a risk factor for coronary heart disease. Current Atherosclerosis Reports. 4: 414-8. PMID 12361487 DOI: 10.1007/S11883-002-0044-0 |
0.343 |
|
| 2002 |
Hong SH, Rhyne J, Zeller K, Miller M. ABCA1Alabama: a novel variant associated with HDL deficiency and premature coronary artery disease Atherosclerosis. 164: 245-250. PMID 12204794 DOI: 10.1016/S0021-9150(02)00106-5 |
0.306 |
|
| 2002 |
Miller M, Jialal I. Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia American Journal of Cardiology. 89: 468-469. PMID 11835933 DOI: 10.1016/S0002-9149(01)02273-1 |
0.339 |
|
| 2002 |
Hong SH, Riley W, Rhyne J, Friel G, Miller M. Lack of Association between Increased Carotid Intima-Media Thickening and Decreased HDL-Cholesterol in a Family with a Novel ABCA1 Variant, G2265T Clinical Chemistry. 48: 2066-2070. DOI: 10.1093/Clinchem/48.11.2066 |
0.32 |
|
| 2001 |
Kasid A, Rhyne J, Zeller K, Pritchard H, Miller M. A novel TC deletion resulting in Pro260→Stop in the human LCAT gene is associated with a dominant effect on HDL-cholesterol Atherosclerosis. 156: 127-132. PMID 11369005 DOI: 10.1016/S0021-9150(00)00640-7 |
0.31 |
|
| 2001 |
Miller M, Dolinar C, Cromwell W, Otvos JD. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. American Journal of Cardiology. 87: 232-234. PMID 11152850 DOI: 10.1016/S0002-9149(00)01327-8 |
0.312 |
|
| 2000 |
Miller M. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial The American Journal of Cardiology. 86. PMID 11374852 DOI: 10.1016/S0002-9149(00)01466-1 |
0.355 |
|
| 2000 |
Miller M. Current perspectives on the management of hypertriglyceridemia American Heart Journal. 140: 232-240. PMID 10925336 DOI: 10.1067/Mhj.2000.108001 |
0.361 |
|
| 2000 |
Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD. Sex Bias and Underutilization of Lipid-Lowering Therapy in Patients With Coronary Artery Disease at Academic Medical Centers in the United States and Canada Jama Internal Medicine. 160: 343-347. PMID 10668836 DOI: 10.1001/Archinte.160.3.343 |
0.323 |
|
| 1999 |
Miller M. New developments in the treatment of low high-density lipoprotein cholesterol Current Atherosclerosis Reports. 1: 24-30. PMID 11122688 DOI: 10.1007/S11883-999-0046-2 |
0.361 |
|
| 1999 |
Miller M. Giving triglycerides their due Hospital Practice. 34: 67-73. PMID 10901761 DOI: 10.3810/Hp.1999.09.1.162 |
0.327 |
|
| 1998 |
Miller M, Aiello D, Pritchard H, Friel G, Zeller K. Apolipoprotein A-I(Zavalla) (Leu159-->Pro): HDL cholesterol deficiency in a kindred associated with premature coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 18: 1242-7. PMID 9714130 DOI: 10.1161/01.Atv.18.8.1242 |
0.34 |
|
| 1998 |
Miller M, Seidler A, Moalemi A, Pearson TA. Normal Triglyceride Levels and Coronary Artery Disease Events: The Baltimore Coronary Observational Long-Term Study Journal of the American College of Cardiology. 31: 1252-1257. PMID 9581716 DOI: 10.1016/S0735-1097(98)00083-7 |
0.33 |
|
| 1995 |
Miller M, Burgan RG, Osterlund L, Segrest JP, Garber DW. A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology. 15: 2151-2156. PMID 7489236 DOI: 10.1161/01.Atv.15.12.2151 |
0.343 |
|
| 1995 |
Corretti MC, Plotnick GD, Miller M, Vogel RA. 786-5 Risk Factor Modification Improves Flow-Mediated Brachial Artery Vasoactivity but not Cold Pressor Vasoactivity in Men with Coronary Artery Disease Journal of the American College of Cardiology. 25: 3-7. DOI: 10.1016/0735-1097(95)92855-Y |
0.302 |
|
| 1993 |
Miller M, Kwiterovich PO, Bachorik PS, Georgopoulos A. Decreased postprandial response to a fat meal in normotriglyceridemic men with hypoalphalipoproteinemia. Arteriosclerosis and Thrombosis : a Journal of Vascular Biology / American Heart Association. 13: 385-92. PMID 8443142 DOI: 10.1161/01.Atv.13.3.385 |
0.312 |
|
| 1993 |
Miller M, Bachorik PS, McCrindle BW, Kwiterovich PO. Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: A randomized, double-blind, placebo-controlled, crossover study The American Journal of Medicine. 94: 7-12. PMID 8420303 DOI: 10.1016/0002-9343(93)90113-4 |
0.337 |
|
| 1992 |
Miller M, Seidler A, Kwiterovich PO, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol Circulation. 86: 1165-1170. PMID 1394924 DOI: 10.1161/01.Cir.86.4.1165 |
0.344 |
|
| 1990 |
Miller M, Mead LA, Kwiterovich PO, Pearson TA. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease The American Journal of Cardiology. 65: 1-5. PMID 2294675 DOI: 10.1016/0002-9149(90)90017-U |
0.337 |
|
| 1990 |
Miller M, Kwiterovich PO. Isolated low HDL-cholesterol as an important risk factor for coronary heart disease European Heart Journal. 11: 9-14. PMID 2073916 DOI: 10.1093/Eurheartj/11.Suppl_H.9 |
0.348 |
|
| 1990 |
Miller M. Therapy for Low High-Density Lipoprotein Cholesterol in the Face of 'Desirable' Levels of Total Cholesterol Jama. 263: 1768-1768. DOI: 10.1001/Jama.1990.03440130048024 |
0.329 |
|
| Show low-probability matches. |
